Weak-binding molecules are not drugs?-toward a systematic strategy for finding effective weak-binding drugs

Briefings in Bioinformatics

Volumn 18, Issue 2, 2017, Pages 321-332

  Wang, Jinan ^a   Guo, Zihu ^a   Fu, Yingxue ^a   Wu, Ziyin ^a   Huang, Chao ^a   Zheng, Chunli ^a   Shar, Piar Ali ^a   Wang, Zhenzhong ^b   Xiao, Wei and ^b   Wang, Yonghua ^a  

^a NORTHWEST A F UNIVERSITY   (China)

^b JIANGSU KANION PHARMACEUTICAL CO   (China)

Author keywords

Mathematical modeling; Polypharmacology; Systems pharmacology; Weak binding drug

Indexed keywords

LIGAND;

DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG INTERACTION; HUMAN;

DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; LIGANDS;

EID: 85018765908     PISSN: 14675463     EISSN: 14774054     Source Type: Journal    
DOI: 10.1093/bib/bbw018     Document Type: Article

References (88)

1. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90.
2. Mestres J, Gregori-Puigjane E. Conciliating binding efficiency and polypharmacology. Trends Pharmacol Sci 2009;30:470-4.
3. Lipton SA. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr Drug Targets 2007;8:621-32.
4. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26:178-82.
5. Tan LT. Bioactive natural products from marine cyanobacte-ria for drug discovery. Phytochemistry 2007;68:954-79.
6. Zhu L, Xu X. Selective separation of active inhibitors of epidermal growth factor receptor from Caragana jubata by molecularly imprinted solid-phase extraction. J Chromatogr A 2003;991:151-8.
7. Liu T, Lin Y, Wen X, et al. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007;35:D198-201.
8. Ohlson S. Designing transient binding drugs: a new concept for drug discovery. Drug Discov Today 2008;13:433-9.
9. Tang J, Aittokallio T. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Curr Pharm Des 2014;20:23-36.
10. Kibble M, Saarinen N, Tang J, et al. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep 2015;32:1249-66.
11. Barneh F, Jafari M, Mirzaie M. Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database. Brief Bioinform 2015. doi: 10.1093/bib/bbv094.
12. Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34:D668-72.
13. Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 2014;42:D1091-7.
14. Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network. Nat Biotechnol 2007;25:1119-26.
15. Nunez S, Venhorst J, Kruse CG. Target-drug interactions: first principles and their application to drug discovery. Drug Discov Today 2012;17:10-22.
16. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov2006;5:160-70.
17. Lu H, Tonge PJ. Drug-target residence time: critical information for lead optimization. Curr Opin Chem Biol 2010;14:467-74.
18. Copeland RA, Pompliano DL, Meek TD. Opinion - Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006;5:730-9.
19. Bottegoni G, Favia AD, Recanatini M, et al. The role of fragment-based and computational methods in polypharmacology. Drug Discov Today 2012;17:23-34.
20. Overington JP, Al-Lazikani B, Hopkins AL. Opinion - How many drug targets are there? Nat Reu Drug Discou 2006;5:993-6.
21. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs? Curr Opin Struct Biol 2006;16:127-36.
22. Cho DY, Kim YA, Przytycka TM. Chapter 5: Network biology approach to complex diseases. Plos Comput Biol 2012;8:e1002820.
23. Korcsmaros T, Szalay MS, Csaba B, et al. How to design multitarget drugs: target search options in cellular networks. Expert Opin Drug Discov 2007;2:799-808.
24. Xie L, Xie L, Kinnings SL, et al. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Reu Pharmacol Toxicol 2012;52:361-79.
25. Lounkine E, Keiser MJ, Whitebread S, et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 2012;486:361-7.
26. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discou Deuel 2010;13:297-309.
27. Rosini M. Polypharmacology: the rise of multitarget drugs over combination therapies. Future Med Chem 2014;6:485-7.
28. Chen B, Wild D, Guha R. PubChem as a source of polypharmacology. J Chem Inf Model 2009;49:2044-55.
29. Csermely P. Strong links are important, but weak links stabilize them. Trends Biochem Sci 2004;29:331-4.
30. Gribbon P, Sewing A. High-throughput drug discovery: what can we exulect from HTS? Drug Discov Today 2005;10:17-22.
31. Wang Y, Xing J, Xu Y, et al. In silico ADME/T modelling for rational drug design. QRev Biophys 2015;48:488-515.
32. Macarron R, Banks MN, Bojanic D, et al. Impact of high-throughput screening in biomedical research. Nat Reu Drug Discou 2011;10:188-95.
33. Vaynberg J, Qin J. Weak protein-protein interactions as probed by NMR spectroscopy. Trends Biotechnol 2006;24:22-7.
34. Ozbal CC, LaMarr WA, Linton JR, et al. High throughput screening via mass spectrometry: a case study using acetyl-cholinesterase. Assay Drug Dev Technol 2004;2:373-81.
35. Nienaber VL, Richardson PL, Klighofer V, et al. Discovering novel ligands for macromolecules using X-ray crystallo-graphic screening. Nat Biotechnol 2000;18:1105-8.
36. Duong-Thi MD, Meiby E, Bergstrom M, et al. Weak affinity chromatography as a new approach for fragment screening in drug discovery. Anal Biochem 2011;414:138-46.
37. Rudnev AV, Aleksenko SS, Semenova O, et al. Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method. J Sep Sci 2005;28:121-7.
38. Rich RL, Myszka DG. Higher-throughput, label-free, real-time molecular interaction analysis. Anal Biochem 2007;361:1-6.
39. Christopher JA, Brown J, Dore AS, et al. Biophysical fragment screening of the beta(1)-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J Med Chem 2013;56:3446-55.
40. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Reu Genet 2011;12:56-68.
41. Araujo RP, Liotta LA, Petricoin EF. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov 2007;6:871-80.
42. Yang K, Bai HJ, Qi OY, et al. Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 2008;4:228.
43. Bianconi F, Baldelli E, Ludovini V, et al. Computational model of EGFR and IGF1R pathways in lung cancer: a systems biology approach for translational oncology. Biotechnol Adv 2012;30:142-53.
44. Fujioka A, Terai K, Itoh RE, et al. Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes. J Biol Chem 2006;281:8917-26.
45. Li P, Fu Y, RuJ, et al. Insights from systems pharmacology into cardiovascular drug discovery and therapy. BMC Syst Biol 2014;8:141
46. Hwang WC, Zhang A, Ramanathan M. Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery. Clin Pharmacol Ther 2008;84:563-72.
47. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-83.
48. Cheng JQ, Lindsley CW, Cheng GZ, et al. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 2005;24:7482-92.
49. Sykiotis GP, Papavassiliou AG. Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol Endocrinol 2001;15:1864-9.
50. Xie L, Evangelidis T, Xie L, et al. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. Plos Comput Biol 2011;7:e1002037.
51. Kitchen DB, Decornez H, Furr JR, et al. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 2004;3:935-49.
52. Kollman PA, Massova I, Reyes C, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 2000;33:889-97.
53. Durrant JD, McCammon JA. Molecular dynamics simulations and drug discovery. BMC Biol 2011;9:71.
54. Yu H, Chen J, Xu X, et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 2012;7:e37608.
55. Zheng C, Guo Z, Huang C, et al. Large-scale direct targeting for drug repositioning and discovery. Sci Rep 2015;5:11970.
56. Yin N, Ma W, Pei J, et al. Synergistic and antagonistic drug combinations depend on network topology. PLoS One 2014;9:e93960.
57. Ma WZ, Trusina A, El-Samad H, et al. Defining network topologies that can achieve biochemical adaptation. Cell 2009;138:760-73.
58. Fitzgerald JB, Schoeberl B, Nielsen UB, et al. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006;2:458-66.
59. Behar M, Barken D, Werner SL, et al. The dynamics of signaling as a pharmacological target. Cell 2013;155:448-61.
60. Shoval O, Alon U. SnapShot: network motifs. Cell 2010;143:326-U158.
61. Mangan S, Alon U. Structure and function of the feed-forward loop network motif. Proc Natl Acad Sci USA 2003;100:11980-5.
62. Goentoro L, Shoval O, Kirschner MW, et al. The incoherent feedforward loop can provide fold-change detection in gene regulation. Mol Cell 2009;36:894-9.
63. Hart Y, Alon U. The utility of paradoxical components in biological circuits. Mol Cell 2013;49:213-21.
64. Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. Semin Immunol 2014;26:237-45.
65. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-12.
66. Ventura JJ, Kennedy NJ, Lamb JA, et al. c-jun NH2-terminal kinase is essential for the regulation of AP-1 by tumor necrosis factor. Mol Cell Biol 2003;23:2871-82.
67. Lee JC, Laydon JT, Mcdonnell PC, et al. A protein-kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-46.
68. Tomida T, Takekawa M, Saito H. Oscillation of p38 activity controls efficient pro-inflammatory gene expression. Nat Commun 2015;6:8350.
69. Ru JL, Li P, Wang JN, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform 2014;6:13.
70. Wang Y, Zheng C, Huang C, et al. Systems pharmacology dissecting holistic medicine for treatment of complex diseases: an example using cardiocerebrovascular diseases treated by TCM. Evid Based Complement Alternat Med 2015;2015:980190.
71. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res 2000;28:235-42.
72. Zhang H, Yao Y, Yang H, et al. Molecular dynamics and free energy studies on the carboxypeptidases complexed with peptide/small molecular inhibitor: mechanism for drug resistance. Insect Biochem Mol Biol 2012;42:583-95.
73. Barrett SD, Bridges AJ, Dudley DT, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett 2008;18:6501-4.
74. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
75. Ohori M, Kinoshita T, Okubo M, et al. Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 2005;336:357-63.
76. Bain J, McLauchlan H, Elliott M, et al. The specificities of protein kinase inhibitors: an update. Biochem J 2003;371:199-204.
77. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthra pyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001;98:13681-6.
78. Eyers PA, Craxton M, Morrice N, et al. Conversion of SB 203580-insensitive MBP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 1998;5:321-8.
79. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
80. Cuenda A, Rouse J, Doza YN, et al. Sb-203580 is a specific inhibitor of a map kinase homolog which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229-33.
81. Tanay A. Extensive low-affinity transcriptional interactions in the yeast genome. Genome Res 2006;16:962-72.
82. Agoston V, Csermely P, Pongor S. Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Physical Rev E Stat Nonlin Soft Matter Phys 2005;71:051909.
83. Huang C, Zheng CL, Li Y, et al. Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform 2014;15:710-33.
84. Kelley LA, Sternberg MJE. Protein structure prediction on the Web: acasestudy usingthe Phyreserver. Nat Protoc 2009;4:363-71.
85. Verdonk ML, Cole JC, Hartshorn MJ, et al. Improved proteinligand docking using GOLD. Proteins 2003;52:609-23.
86. Xu SG, Li SQ, Guo ZF, et al. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. Mol CancerTher 2013;12:1665-75.
87. Meng JR, Dai BB, Fang BL, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 2010;5:e14124.
88. Kim JE, Son JE, Jang YJ, et al. Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells. J Pharmacol Exp Ther 2011;338:1013-22.